- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00442039
Lithium for the Treatment of Pediatric Mania
February 24, 2012 updated by: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Pediatric Pharmacokinetic and Tolerability Study of Lithium for the Treatment of Pediatric Mania Followed by an Open Label Long Term Safety Period, Discontinuation Phase, and Restabilization Period.
This clinical trial is being performed under the Best Pharmaceuticals for Children Act, signed into law in 2002 in order to improve pediatric labeling for off-patent drugs.
The purpose of this study is to examine the efficacy and safety of lithium in the treatment of pediatric patients with bipolar I disorder.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
This is a multiphase, multicenter, trial that will comprehensively examine lithium in the treatment of pediatric patients with bipolar I disorder.
In order to examine the treatment of bipolar disorder with lithium, this study will include four phases of treatment.
The first phase, the Pharmacokinetic Phase, will include 8 weeks of Open Label treatment to determine empirically based dosing strategies for children and adolescents with bipolar disorder.
Patients completing the Pharmacokinetic Phase, may be eligible to continue in the Long-Term Effectiveness Phase for a maximum of 16 weeks of lithium treatment.
Subsequently, patients meeting response criteria during the Long-Term Effectiveness Phase will be eligible to continue in the Discontinuation Phase.
During the Discontinuation Phase, patients will be randomized to either placebo or lithium treatment for up to 28 weeks.
Finally, those subjects who experience a mood relapse during the Discontinuation Phase will be enrolled in an Open Label Restabilization Phase and treated with lithium for up to 8 weeks.
Study Type
Interventional
Enrollment (Actual)
61
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44126
- Case Western Reserve University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
7 years to 17 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The patient was between the ages of 7 years and 17 years, 11 months at time of first dose.
- The patient met DSM-IV diagnostic criteria, as assessed by a semi-structured assessment (Kiddie Schedule for Affective Disorders and Schizophrenia - Present and Lifetime [KSADS-PL]) and a separate clinical interview with a child/adolescent psychiatrist for manic or mixed episodes in Bipolar I disorder.
- The patient had a score of ≥ 20 on the YMRS at screening and baseline.
- The patient and legal guardian understood the nature of the study and were able to comply with protocol requirements. The legal guardian gave written informed consent and the youth, written assent.
- Patients with comorbid conditions (attention deficit hyperactivity disorder [ADHD], conduct disorder) were eligible to participate.
- If female: the patient was premenarchal, or was incapable of pregnancy because of a hysterectomy, tubal ligation, or spousal/partner sterility. If sexually active and capable of pregnancy, the patient must have been using an acceptable method of contraception (hormonal contraceptives, intrauterine device, spermicide and barrier) for at least 1 month prior to study entry and agreed to continue to use one of them for the duration of the study. If sexually abstinent and capable of pregnancy, the patient agreed to continue abstinence or to use of an acceptable method of birth control (either intrauterine device or spermicide and barrier) should sexual activity commence.
- If female, the patient had a negative quantitative serum ß-human chorionic gonadotrophin hormone pregnancy test at screening and a negative qualitative urine pregnancy test at baseline, if female.
- Patients with a history of substance abuse were eligible to participate if they agreed to continue to abstain from drugs during the trial and had a negative drug screen at screening or prior to baseline.
- The patient was willing and clinically able to washout (approximately 5 half-lives) of exclusion medications during the screening period and prior to the administration of lithium. (No stable patients were asked to discontinue medications.)
- The patient"s ECG and blood work (including complete blood count [CBC], electrolytes, etc.) showed no clinically significant abnormalities.
Exclusion Criteria:
- The patient was clinically stable on current medication regiment for bipolar disorder.
- The patient had a current or lifetime diagnosis of Schizophrenia or Schizoaffective Disorder, a Pervasive Developmental Disorder (Austin Screening Questionnaire score > 15), Anorexia Nervosa, Bulimia Nervosa, or Obsessive-Compulsive Disorder.
- The patient had a current DSM-IV diagnosis of Substance Dependence.
- The patient had a positive drug screen at screening and on retest 1-3 weeks later.
- The patient had symptoms of mania that may have been attributable to a general medical condition, or secondary to use of medications (eg, corticosteroids)
- The patient had evidence of any serious and/or unstable neurological illness for which treatment under the auspices of this study would have been contra-indicated.
- The patient had any serious, unstable medical illness or clinically significant abnormal laboratory assessments that would adversely impact the scientific interpretability or unduly increase the risks of the protocol.
- The patient had a current general medical condition including neurological disease, diabetes mellitus, thyroid dysfunction, or renal dysfunction that might have been affected adversely by lithium, could have influenced the efficacy or safety of lithium, or would have complicated interpretation of study results.
- The patient had evidence of current serious homicidal/suicidal ideation such that in the treating physician's opinion it was appropriately safe for the patient to participate in this study.
- The patient had evidence of current active hallucinations and delusions such that in the treating physician's opinion it was not appropriately safe for the patient to participate in this study.
- The patient had concomitant prescription of over-the-counter medication or nutritional supplements that would interact with lithium or the patient"s physical or mental status.
- The patient had any use of psychotropic agents other than stimulants within the preceding 2 weeks, including antipsychotics, monoamine oxidase inhibitors, antidepressants; use of stimulants within the preceding week; or fluoxetine or depot antipsychotics within the past month.
- The patient had current psychotherapy treatments provided outside the study initiated within 4 weeks prior to screening.
- The patient had a previous adequate trial with lithium (at least 4 weeks with lithium serum levels between 0.8-1.2 mEq/L).
- The patient had a history of allergy to lithium.
- The patient had psychiatric hospitalization within 1 month of screening for psychosis or serious homicidal/serious suicidal ideation.
- Clinician"s judgment was that the patient was not likely to be able to complete the study as an outpatient due to psychiatric reasons.
- The patient had a history of lithium intolerance.
- Females who were currently pregnant or lactating.
- Sexually active females who, in the investigators" opinion, were not using an adequate form of birth control.
- Patients who were unable to swallow the study medication.
- Patients for whom a baseline YMRS score of < 20 was anticipated.
- Patients with an IQ < 70 (determined using the Wechsler Abbreviated Scales of Intelligence [WASI] Vocabulary and Matrix Reasons Subscales).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
During the third phase, which is the Discontinuation Phase, patients will be randomized to either placebo or lithium treatment for up to 28 weeks.
|
Experimental: Lithium dosing 1
The starting dose of lithium was 300 mg for patients weighing < 20 kg [no patients were enrolled that weighed less than 20 kg] and 600 mg for patients weighing ≥ 20 kg.
|
The starting dose of lithium was 300 mg for patients weighing < 20 kg
The dose of lithium was increased weekly by 300 mg to maximum tolerated dose depending upon the patient"s response and tolerability.
The starting dose of lithium was 900 mg and the dose of lithium was increased weekly by 300 mg to maximum tolerated dose depending upon the patient"s response and tolerability
The starting dose of lithium was 900 mg and the lithium dose was increased by 300 mg every 3 days, (no more than twice weekly) to maximum tolerated dose based upon the patient"s response and tolerability.
|
Experimental: Lithium dosing 2
The starting dose of lithium was 900 mg and the dose of lithium was increased weekly by 300 mg to maximum tolerated dose depending upon the patient"s response and tolerability.
|
The starting dose of lithium was 300 mg for patients weighing < 20 kg
The dose of lithium was increased weekly by 300 mg to maximum tolerated dose depending upon the patient"s response and tolerability.
The starting dose of lithium was 900 mg and the dose of lithium was increased weekly by 300 mg to maximum tolerated dose depending upon the patient"s response and tolerability
The starting dose of lithium was 900 mg and the lithium dose was increased by 300 mg every 3 days, (no more than twice weekly) to maximum tolerated dose based upon the patient"s response and tolerability.
|
Experimental: Lithium dosing 3
The starting dose of lithium was 900 mg and the lithium dose was increased by 300 mg every 3 days, (no more than twice weekly) to maximum tolerated dose based upon the patient"s response and tolerability.
|
The starting dose of lithium was 300 mg for patients weighing < 20 kg
The dose of lithium was increased weekly by 300 mg to maximum tolerated dose depending upon the patient"s response and tolerability.
The starting dose of lithium was 900 mg and the dose of lithium was increased weekly by 300 mg to maximum tolerated dose depending upon the patient"s response and tolerability
The starting dose of lithium was 900 mg and the lithium dose was increased by 300 mg every 3 days, (no more than twice weekly) to maximum tolerated dose based upon the patient"s response and tolerability.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Mean Change in YMRS summary score by treatment
Time Frame: 8 weeks
|
Measure of efficacy
|
8 weeks
|
Mean change in YMRS parent score
Time Frame: 8 weeks
|
Measure of efficacy
|
8 weeks
|
Mean change in YMRS child score
Time Frame: 8 weeks
|
Measure of efficacy
|
8 weeks
|
Rate of treatment emergent adverse events
Time Frame: During administration of study drug
|
During administration of study drug
|
|
Dosing - PK
Time Frame: 8 weeks
|
8 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Robert L Findling, MD, Case Western University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Findling RL, McNamara NK, Pavuluri M, Frazier JA, Rynn M, Scheffer R, Kafantaris V, Robb A, DelBello M, Kowatch RA, Rowles BM, Lingler J, Zhao J, Clemons T, Martz K, Anand R, Taylor-Zapata P. Lithium for the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled Discontinuation Study. J Am Acad Child Adolesc Psychiatry. 2019 Feb;58(2):287-296.e4. doi: 10.1016/j.jaac.2018.07.901. Epub 2018 Nov 26.
- Findling RL, Frazier JA, Kafantaris V, Kowatch R, McClellan J, Pavuluri M, Sikich L, Hlastala S, Hooper SR, Demeter CA, Bedoya D, Brownstein B, Taylor-Zapata P. The Collaborative Lithium Trials (CoLT): specific aims, methods, and implementation. Child Adolesc Psychiatry Ment Health. 2008 Aug 12;2(1):21. doi: 10.1186/1753-2000-2-21.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2006
Primary Completion (Actual)
April 1, 2009
Study Completion (Actual)
September 1, 2009
Study Registration Dates
First Submitted
February 27, 2007
First Submitted That Met QC Criteria
February 27, 2007
First Posted (Estimate)
March 1, 2007
Study Record Updates
Last Update Posted (Estimate)
February 28, 2012
Last Update Submitted That Met QC Criteria
February 24, 2012
Last Verified
February 1, 2012
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Mania
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Enzyme Inhibitors
- Tranquilizing Agents
- Psychotropic Drugs
- Antidepressive Agents
- Antimanic Agents
- Lithium Carbonate
Other Study ID Numbers
- NICHD-2005-07-01
- DUNS No. 07-775-8407
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bipolar I Disorder Without Psychotic Symptoms
-
University of Texas Southwestern Medical CenterNational Institute of Mental Health (NIMH); Beth Israel Deaconess Medical Center and other collaboratorsCompletedBipolar I Disorder, Unspecified, With Psychotic Features | Bipolar I Disorder, Unspecified, Without Psychotic FeaturesUnited States
-
Otsuka Pharmaceutical Development & Commercialization...TerminatedAdolescent Schizophrenia | Child or Adolescent Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic FeaturesIndia, United States, Bulgaria, Croatia, Hungary, Malaysia, Philippines, Poland, Romania, Russian Federation, Serbia, Taiwan, Ukraine
-
Mclean HospitalBeth Israel Deaconess Medical CenterNot yet recruitingSchizophrenia | Schizoaffective Disorder | Psychosis | Bipolar Disorder IUnited States
-
Mclean HospitalMassachusetts General HospitalCompletedSchizophrenia | Schizoaffective Disorder | Bipolar Disorder IUnited States
-
University of North Carolina, Chapel HillFoundation of Hope, North CarolinaCompletedSchizophrenia | Schizoaffective Disorder | Schizophreniform Disorder | Autistic Disorder | Child Development Disorders, Pervasive | Psychosis NOS | Bipolar I Disorder | Asperger Syndrome | Bipolar II Disorder | Severe Major Depression With Psychotic Features | Mood Disorder NOS | Single Episode Major Depression... and other conditionsUnited States
-
BioXcel Therapeutics IncCognitive Research CorporationRecruitingSchizophrenia | Bipolar Disorder I | Schizo-Affective Disorder | Schizophreniform; Schizophrenic | Bipolar Disorder IIUnited States
-
Nantes University HospitalCR2TI, INSERM, UMR1064RecruitingBipolar Disorder I | Bipolar Disorder II | Schizoaffective Disorder, Depressive TypeFrance
-
diaMentis Inc.Active, not recruitingSchizophrenia | Bipolar I DisorderUnited States, Australia, Canada
-
Alkermes, Inc.CompletedSchizophrenia | Schizophreniform Disorder | Bipolar I DisorderUnited States, Bulgaria, Russian Federation, Ukraine, Austria, Ireland, Israel, Italy, Korea, Republic of, Poland, United Kingdom, Serbia, Puerto Rico
-
Mclean HospitalBaszucki Family FoundationRecruitingSchizoaffective Disorder | Psychosis | Bipolar I DisorderUnited States
Clinical Trials on Lithium Carbonate
-
Northwestern UniversityCompletedBipolar DisorderUnited States
-
Shanghai Mental Health CenterUnknown
-
New York State Psychiatric InstituteNational Institute on Aging (NIA)CompletedPsychosis | Alzheimer's Disease | AgitationUnited States
-
The University of Hong KongChina Spinal Cord Injury NetworkCompletedSpinal Cord InjuriesChina
-
University of Wisconsin, MadisonTerminatedMedullary Thyroid CancerUnited States
-
Brigham and Women's HospitalRecruitingDepression | Bipolar Disorder | Bipolar Depression | Major Depressive Episode | Bipolar I Depression | Bipolar II DepressionUnited States
-
University of Maryland, BaltimoreCompletedOsteoporosis PseudogliomaUnited States
-
University of OxfordCompleted
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedPrimary Myelofibrosis | Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal... and other conditionsUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)TerminatedSolid Tumor | Brain and Central Nervous System Tumors | Neurotoxicity | Cognitive/Functional EffectsUnited States